| Serial Number | 79330615 |
| Word Mark | CT CELLENGENE CELL AND GENE THERAPY |
| Filing Date | Friday, November 19, 2021 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, May 2, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | NOT AVAILABLE |
| Description of Mark | The mark consists of the wording "CT CELLENGENE CELL AND GENE THERAPY". The letter "C" in "CT" is red; the letter "T" is yellow. The letter "C" in "CELLENGENE" is red; the rest of the letters are black. The wording "CELL AND GENE THERAPY" is in black. |
| Description of the Colors Claimed | The color of the background is white; also, the letters 'C' are colored in red and the letter 'T' is colored in yellow; the remaining letters are all black. |
| Goods and Services | Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer; stem cells for medical purposes; antidiabetic preparations; anti-diabetic pharmaceuticals; anti-cancer preparations |
| Indication of Colors claimed | The color(s) red, yellow, and black is/are claimed as a feature of the mark. |
| Goods and Services | Medical services in the field of diabetes; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; health care services for treating cancer; medical services relating to the removal, treatment and processing of human cells; medical analysis relating to clinical data, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories |
| NOT AVAILABLE | "CELL AND GENE THERAPY" |
| Goods and Services | Development of cell therapy products, namely, research and development and consultation related thereto in the field of cell engineering technology; scientific research for medical purposes in the area of cancerous diseases; research services relating to pharmaceuticals, namely, stem cell research services; stem cell research services |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Cellengene Inc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Wednesday, September 14, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, January 6, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, January 7, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 11, 2022 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, August 31, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, September 13, 2022 | NON-FINAL ACTION WRITTEN |
| Monday, November 7, 2022 | REFUSAL PROCESSED BY MPU |
| Monday, November 7, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sunday, November 27, 2022 | REFUSAL PROCESSED BY IB |
| Thursday, December 1, 2022 | LETTER OF PROTEST EVIDENCE FORWARDED |
| Thursday, December 22, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, December 22, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 22, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, January 30, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, January 30, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, January 30, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, June 7, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, June 7, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Wednesday, July 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, July 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, June 26, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Wednesday, July 26, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 2, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Thursday, May 2, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Friday, October 20, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, October 20, 2023 | FINAL REFUSAL WRITTEN |
| Friday, October 20, 2023 | FINAL REFUSAL E-MAILED |